Mesirow Financial Investment Management, Inc. Syndax Pharmaceuticals Inc Transaction History

Mesirow Financial Investment Management, Inc.

$4.3 Billion
Q2 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 16, 2024	BUY	$18.82 - $23.79 $232,332 - $293,687	12,345 New	12,345 $253 Million
Q1 2024 Apr 19, 2024	SELL	$19.71 - $24.57 $73,045 - $91,056	-3,706 Reduced 23.13%	12,318 $293 Million
Q4 2023 Jan 10, 2024	BUY	$11.39 - $21.67 $42,609 - $81,067	3,741 Added 30.46%	16,024 $346,000
Q2 2023 Jul 14, 2023	BUY	$19.35 - $22.31 $237,676 - $274,033	12,283 New	12,283 $257,000
Q2 2021 Jul 23, 2021	SELL	$13.42 - $25.18 $11,997 - $22,510	-894 Closed	0 $0
Q1 2021 Apr 14, 2021	BUY	$19.28 - $24.59 $7,364 - $9,393	382 Added 74.61%	894 $20,000
Q4 2020 Jan 14, 2021	BUY	$15.1 - $26.44 $7,731 - $13,537	512 New	512 $11,000

Others Institutions Holding SNDX

# of Institutions

202

Shares Held

87.1M

Call Options Held

268K

Put Options Held

76.8K

Black Rock Inc. New York, NY

7.91M
Shares

$151 Million
0.0% of portfolio
Wellington Management Group LLP Boston, MA

7.34M
Shares

$140 Million
0.03% of portfolio
Kynam Capital Management, LP Princeton, NJ

5.72M
Shares

$109 Million
9.15% of portfolio
Vanguard Group Inc Valley Forge, PA

4.8M
Shares

$91.6 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

3.89M
Shares

$74.3 Million
1.09% of portfolio

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.08B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mesirow Financial Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mesirow Financial Investment Management, Inc. with notifications on news.

Account